Original Research Article

Detection of the Prevalence of Multidrug-Resistant Tuberculosis Notified in Abu Anga Hospital, Khartoum State, Sudan (2020–2022)

ABSTRACT

Background: In 2020, there were 5.8 million cases of tuberculosis worldwide, making it a substantial public health concern. Drug-resistant strains of Mycobacterium tuberculosis, which are characterized by increased morbidity and mortality, have become a significant threat to the global control of tuberculosis. ***Objective:*** To determine the prevalence of multidrug-resistant tuberculosis reported at Abu Anga Hospital in Khartoum State between 2020 and 2022 is the goal of this investigation. ***Materials and Methods:*** A total of 204 samples were used in this retrospective analysis to identify MTB/RIF. From January 2020 to December 2022, use the Gene Xpert MTB/RIF assay to quickly identify M. tuberculosis complex (MTBC) strains and identify rifampicin-associated mutations of the rpoB gene directly from sputum samples. ***Results:*** All of the samples (204) tested positive for MTB and drug resistance; the majority of new diagnoses (134, 65.7%) were found in comparison to other MDR-TB categories; the prevalence of MDR-TB in 2020 was 49, 24.0%; it increased in 2021 to 97, 47.5%; and it successfully declined in 2022 to 58, 28.5%. Males accounted for the highest burden, accounting for 134 (65.7%) of all cases; 193 (94.6%) showed pulmonary TB in comparison to other types of tuberculosis; rifampicin resistance showed higher resistance among all drug-resistant. ***Conclusions:*** Since tuberculosis (TB) is the second most common infectious disease-related cause of mortality globally, particularly in individuals with co-occurring HIV and TB, its detection and treatment remain top priorities for all nations. According to the study's findings, MDR was more common. Pulmonary tuberculosis was the most common kind of tuberculosis in 2021, and rifampicin was the most common drug-resistant type. These results add to the plight of Khartoum's TB and antibiotic-resistant conditions.

Keywords: MDR-TB, Prevalence, Rifampicin, Tuberculosis, Sudan

1. INTRODUCTION

Up until the middle of the 20th century, tuberculosis (TB) was believed to be incurable. As shown by Crofton in 19591, the advent of anti-TB medications altered the course of TB patients' lives (Sir John Crofton passed away on November 3, 2009, at the years of 97) **[1].** According to estimates from the World Health Organization (WHO), more than 10 million individuals worldwide contracted tuberculosis (TB) between 2017 and 2018 **[2],** In addition to their socioeconomic impact, tuberculosis (TB) and multidrug-resistant TB (MDR-TB) continue to pose a danger to global public health **[3].** During the COVID-19 pandemic, the most noticeable effect was a significant worldwide drop in the number of newly diagnosed TB cases, which fell from 7.1 million in 2019 to 5.8 million in 2020, according to WHO data in the 2021 Global Tuberculosis Report. TB mortality has gone up due to limited access to TB diagnosis and treatment. TB will claim 1.3 million lives worldwide in 2020 **[5].** The two main medications used to treat tuberculosis are rifampicin (RIF) and isoniazid (INH). Ethambutol (EMB), streptomycin (STM), and pyrazinamide (PZA) are the other first-line medications **[3].** The 85% and 70% treatment success targets are explained by the risk of tuberculous infection and its trend, which is crucial in controlling the TB pandemic. Even when HIV is present, the detection of smear-positive TB cases can help reduce the TB burden **[9].** MDR-TB, or multidrug-resistant tuberculosis, is characterized by resistance to at least isoniazid and rifampicin **[4].** Patients with relapses and failures had higher levels of rifampicin resistance (RR-MTB). In 2018, there were almost half a million new cases of rifampicin-resistant (RR) TB, 78% of which had MDR TB **[6].** According to WHO (2021), up to 71% of the world's population, or 2.1 million people, received a diagnosis of bacteriological tuberculosis in 2020, which is drug-resistant to rifampin **[5].** High HIV prevalence and a delay in early diagnosis and effective treatment initiation are linked to the high burden of TB and MDR-TB in low-income countries **[6].** Sudan accounted for 14.6% of the total TB burden and was ranked second in the East Mediterranean area for TB incidence (WHO, 2007) **[3].** Drug resistance may potentially be a consequence of the initial infection. Therefore, to address this, substantial measures are usually required. Compared to susceptible treatments, the second-line drugs of MDR-TB are characterized by higher treatment costs, longer therapy durations, lower efficacy, and

more adverse treatment effects **[2].** TB produced by M tuberculosis isolates that are resistant to rifampicin, isoniazid, and fluoroquinolones, and at least one of the second-line injectable medications (capreomycin, kanamycin, and amikacin) is known as extensively drug-resistant TB (XDR TB) **[7].** Programs for disease management and control must prioritize early treatment initiation, ongoing surveillance, frequent monitoring, and rapid diagnosis of drug-resistant TB. To mitigate the issue of early TB diagnosis in low-income nations **[6].** According to the WHO, one of the main reasons disease resistance exists is because Directly Observed Treatment (DOT) has not been implemented. Furthermore, suboptimal therapy procedures have a direct impact on resistance to anti-TB medications, which is a reflection of the low caliber of TB programs in many nations **[8].** Consequently, this study aimed to detect the Prevalence of Multidrug-Resistant Tuberculosis Notified in Abu Anga Hospital, Khartoum State, Sudan, to help with future management strategies and to provide guidance on the potential ways to control the spread of MDR-TB in Sudan.

2. METHODOLOGY

This retrospective study aimed to identify the prevalence of Multidrug-Resistant Tuberculosis (MDR-TB) among TB patients in Khartoum State from January 2020 to December 2022. The hospital-based investigation took place at Abu Anga Hospital, the specialized facility in Sudan that receives referrals for suspected tuberculosis cases, provides medical services to the population of Khartoum, and functions as Sudan's primary MDR-TB reference hospital, where all documentation and reporting procedures are centralized. All MDR-TB patients recorded at the hospital during the study period were consecutively targeted for inclusion. Cases were included only if they were reported at Abu Anga Hospital and laboratory-confirmed as MDR-TB by GeneXpert testing between 2020 and 2022, while cases reported at the hospital without GeneXpert confirmation of MDR-TB were excluded.

Sampling and sample size

The study focused on all hospitalized patients, regardless of gender or age, who were registered between 2020 and 2022. During this time, 204 MDR-TB patients were recorded; as there was a cap on the total number of patients, all patients were recruited without any sampling.

Data analysis

To process the data, appropriate statistical treatments and equations were used through the statistical software. After completing the study data collection, it was sorted, coded, and then analyzed, and the researcher entered the data of this sample into a computer using Statistical Packaged for Social Science (SPSS) (version 23), the researcher used of several tests and statistical methods "descriptive statistics (Frequency and Percentage) to describe the sample data', chi-square test, And run to summarize continuous and categorical variables of the socio demographic and clinical factors; the predictors were identified and considered significant at a P-value less than 0.05.

3. RESULTS

Table 1. Distribution of demographic data for MDR.TB patients

Age	Frequency	Percent %
0-15	7	3.4%
16-30	120	59.3%
31-45	59	28.4%
more than 45	18	8.9%
Gender		
Male	134	65.70%
Female	70	34.30%
Nationality		
North Sudan	196	96.1%
South Sudan	6	2.9%
Other	2	1%
Patient occupation		
Employed	14	6.9%
Self employed	107	52.5%
Without job	83	40.6%

Table 2. Frequency of MDR.TB categories

MDR. TB categories	Frequency	Percent %
New case	134	65.7%
Failure in treatment	33	16.2%
Lots of follow-up	21	10.3%
Relapse	16	7.8%
Total	**204**	**100%**

Table 3: Frequency of Type drug resistance

Type of drug resistance	Frequency	Percent %
INH	1	0.5%
RR	162	79.4%
MDR	41	20.1%

XDR	0	0%
Total	**204**	**100%**

Table 4. Frequency of Treatment outcome

Treatment outcome	Frequency	Percent %
Cure	57	27.9%
Treatment Complete	58	28.4%
Treatment failure	13	6.4%
Died	18	8.8%
Lots of follow-up	20	9.8%
Not evaluate	34	16.7%
Transfer out	4	2%
Total	**204**	**100%**

Table 5. The correlation between Clinical characteristics of MDR.TB patients and MDR.TB categories

variables		MDR.TB categories				Total	*P.value*
		New case	Failure in treatment	Lots of follow-up	Relapse		
years of diagnosis	2020	26 (19.4%)	10(30.3%)	2 (9.5%)	11(68.8%)	49(24.0%)	0.00
	2021	60 (44.8%)	19(57.6%)	15 (71.4%)	3 (18.8%)	97(47.5%)	
	2022	48 (35.8%)	4 (12.1%)	4 (19.0%)	2 (12.5%)	58(28.5%)	
Age	0-15	5 (3.7%)	-	-	2(12.5%)	7(3.4%)	0.00
	16-30	64 (47.8%)	29(87.9%)	17 (81.0%)	11(68.8%)	120(59.3%)	
	31-45	48 (35.8%)	4(12.1%)	4 (19.0%)	2 (12.5%)	59 (28.4%)	
	≥ 45	17 (12.7%)	-	-	1 (6.3%)	18 (8.9%)	
Gender	Male	64(47.8%)	33(100%)	21(100%)	16(100%)	134(65.7%)	0.00
	Female	70(52.2%)	-	-	-	70(34.3%)	
Nationality	North Sudan	127(94.8%)	33(100%)	21(100%)	15(93.8%)	196(96.1%)	0.211
	South Sudan	6(4.5%)	-	-	-	6(2.9%)	
	other	1(0.7%)	-	-	1(6.3%)	2(1%)	
Patient	Employed	14(10.4%)	-	-	-	14(6.9%)	

occupation	Self employed	101(75.4%)	6(18.2%)	-	-	107(52.5%)	0.00
	Without job	19(14.2%)	27(81.8%)	21(100%)	16(100%)	83(40.6%)	
Class of tuberculosis	Pulmonary	124(92.5%)	33(100%)	21(100%)	15(93.8%)	193(94.6%)	0.238
	Extra pulmonary	10(7.5%)	-	-	1(6.2%)	11(5.4%)	
HIV infection	Positive	6(4.5%)	-	-	-	6(2.9%)	0.358
	Negative	128(95.5%)	33(100%)	21(100%)	16(100%)	198(97.1%)	
Type of drug resistance	INH	1(0.7%)	-	-	-	1(0.5%)	0.00
	RR	117(87.4%)	23(69.7%)	19(90.5%)	3(18.8%)	162(79.4%)	
	MDR	16(11.9%)	10(30.3%)	2(9.5%)	13(81.3%)	41(20.1%)	

Table 6. The correlation between Treatment outcome and MDR.TB categories

Treatment outcome	**variables**	**MDR.TB categories**				**Total**	**P. value**
		New cases	**Failure treatment**	**Loss of follow-up**	**Relapse**		
Cure	**Count**	55	1	0	1	57	**0.00**
	%	41.0%	3.0%	0.0%	6.3%	27.9%	
Treatment Complete	**Count**	36	21	1	0	58	
	%	26.9%	63.6%	4.8%	0.0%	28.4%	
Treatment failure	**Count**	13	0	0	0	13	
	%	9.7%	0.0%	0.0%	0.0%	6.4%	
Died	**Count**	2	0	7	9	18	
	%	1.5%	0.0%	33.3%	56.3%	8.8%	
Loss of follow-up	**Count**	8	7	3	2	20	
	%	6.0%	21.2%	14.3%	12.5%	9.8%	
Not evaluate	**Count**	20	4	7	3	34	
	%	14.9%	12.1%	33.3%	18.8%	16.7%	
Transfer out	**Count**	0	0	3	1	4	
	%	0.0%	0.0%	14.3%	6.3%	2.0%	
Total	**Count**	134	33	21	16	204	
	%	100.0%	100.0%	100.0%	100.0%	100.0%	

4. DISCUSSION

Global TB control is often seen as being seriously threatened by the advent of multidrug-resistant tuberculosis (MDR-TB) and, more recently, extensively drug-resistant TB (XDR-TB). Every year, more than 400,000 new cases of MDR-TB are reported, and XDR-TB cases have been found in every nation with the ability to detect them, even though their rates are currently unknown. Strains, the kind of mutations they include, and their frequency in the mycobacterial genome differ depending on the geographic location **[11,12].** Therefore, success measures for these diagnostic procedures on a country-by-country basis may be contentious because the accuracy of current molecular diagnostic assays to identify MDRTB is reliant on global polymorphism frequencies. For instance, although being found in 100% of resistant strains in nations like Turkey, Canada, and France, the S315T (katG) polymorphism exhibits a large range in prevalence **[13–15].** In the current study, the age group of 16–31 had a greater frequency of MDR, and the total sample number was 204. TB 121 (59.3%) and 134 (65.70%) more often in men than in women. Our results are in line with the 2021 study conducted by Araya Gebreyesus Wasihum and associates **[6],** and S.A. Aricha and his colleagues in 2017 **[10]** demonstrated that the frequency of infection was higher in men than in women. Although more research is required to confirm this point, the reasons for these gender differences may be preferable to the work conditions and immunity status of men compared to women. When compared to other groups, the self-employed group had a higher incidence of 107 (52.5%), indicating low economic status and inadequate health education. Six individuals (2.9%) had HIV co-infection, according to the current study. However, HIV/AIDS is a contributing factor to poor treatment outcomes; according to a 2019 study by Monadil H. Ali et al. **[2],** patients with MDR-TB who were HIV/AIDS-positive had a threefold higher risk of dying than seronegative patients. This is most likely because second-line TB medications and antiretroviral therapy have serious interactions. Of the MDR TB categories, 134 (65.7%) were new cases, 33 (16.2%) did not respond to first-line medication treatment, 21 (10.3%) did not receive follow-up, and 16 (27.2%) exhibited multidrug resistance recurrence. According to our research, rifampicin had a high rate of drug resistance (162; 79.4%), followed by multidrug resistance (41; 20.1%; resistance to several drug types) and isoniazid 1 (0.51%). In contrast, there were no

documented cases of substantial drug resistance in XDR. 51 instances showed negative outcomes (deaths, treatment failure, and loss of follow-up); 115 cases showed successful treatment (cure and treatment complete); 4 cases were in the remaining transferred group, and 34 cases were in the not-evaluated group. According to the varying rate of MDR-TB, 49 cases were reported in 2021, 97 cases in 2021, and 58 cases in 2022. The central system for therapy may be impaired, and patient loss follow-up may be the cause. The study did not find any significant correlation between MDR.TB categories and nationality, class of TB, or HIV co-infection, but it did find a significant correlation between MDR.TB categories and years of diagnosis, demographic information (age, gender, and patient occupation), and type of drug resistance (P value less than 0.05). Additionally, our research revealed a strong relationship (P value <0.05) between MDR.TB categories and treatment outcome.

5. CONCLUSION

The study found that in 2021, the rate of MDR TB reached a record high and that males had a high incidence of infection, a reduced frequency of co-infection with HIV, and a high incidence of new MDR cases. TB classifications, however, the rifampicin registry demonstrates the highest level of medication resistance and a noteworthy association between MDR. The most outcome-oriented treatment is recorded in TB categories with treatment outcomes and cure instances.

CONSENT

The patient's written consent has been collected.

ETHICAL APPROVAL

The study was approved by the Department of Medical Microbiology in Medical Laboratory Sciences at Shendi University, and the study was matched to the ethical review committee board. Sample collection was done after signing a written agreement with the participants. Permission for this study was obtained from the local authorities in the study area. This study's aims and benefits were explained with the assurance of confidentiality. All protocols in this study were done according to the Declaration of Helsinki (1964).

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

As a result, the Author (s) declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during the writing or editing of manuscripts.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that they have no known competing financial interests OR non-financial interests OR personal relationships that could have appeared to influence the work reported in this paper.

REFERENCE

1. Paris, France, and 2 WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy. Drug-resistant tuberculosis: Past, present, future. Journal compilation © Asian Pacific Society of Respirology. Respirology (2010) 15, 413–432 doi: 10.1111/j.1440-1843.2010.01738.x.
2. Monadil H Ali, Alian A Alrasheedy, Dan Kibuule, Brian Godman, Mohamed Azmi Hassali & Hamdan Mustafa Hamdan Ali . Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications, Expert Review of Anti-infective Therapy, (2019). 17:11, 927-937, doi: 10.1080/14787210.2019.1689818.
3. S.O. Hassan, M.T. Musa , H.M. Elsheikh , A.M.S. Eleragi and N.S. Saeed. Drug Resistance in Mycobacterium tuberculosis Isolates from Northeastern Sudan. British Journal of Medicine & Medical Research 2(3). (2012): 424-433.
4. Olusoji Daniel1, Eltayeb Osman.Prevalence and risk factors associated with drug resistant TB in South West, Nigeria. Asian Pacific Journal of Tropical Medicine. (2011), 148-151.
5. Nurul Dwi Andriani , Resta Dwi Yuliani. Meta-Analysis: Risk Factors Associated with Multidrugs-Resistant Tuberculosis (MDR-TB) in Tuberculosis Patients.

Journal of Health Promotion and Behavior. (2021), 06(03): 233-249.

6. Araya Gebreyesus Wasihun . Genet Gebrehiwet Hailu . Tsehaye Asmelash Dejene. prevalence of Mycobacterium tuberculosis (RifampicinResistant MTB) and Associated Risk Actors Among Pulmonary Presumptive TB Patients in Eastern Amhara, Ethiopia: 2015–2019. Infect Diseases.(2021). 10:1299–1308.
7. Kartik Kumar and Ibrahim Abubakar .Clinical implications of the global multidrug-resistant tuberculosis epidemic. Infectious Disease Tuberclosis: Clinical Medicine (2015) .Vol 15, No 6: s37–s42.
8. Monadil H. Ali, Alian A. Alrasheedy, Mohamed Azmi Hassali , Dan Kibuule and Brian Godman. Predictors of Multidrug-Resistant Tuberculosis (MDR-TB)in Sudan ,Antibiotics ,(2019),8,90; doi:10.3390/antibiotics8030090.
9. Chen-yuan chiang, catharina vav weezenbeek, toru mori and donald a. Enarson. Challenges to the global control of tuberculosis. Asian Pacific Society of Respirology ,(2013) 18, 596–604 doi: 10.1111/resp.12067.
10. Aricha , L. Kingwara, N. W. Mwirigi , L. Chaba , T. Kiptai , J. Wahogo, et al. Comparison of GeneXpert and line probe assay for detection of Mycobacterium tuberculosis and rifampicin-mono resistance at the National Tuberculosis Reference Laboratory, Kenya .Research article.(2019). doi.org/10.1186/s12879-019-4470-9.
11. Filliol, A.S. Motiwala, M. Cavatore, W. Qi, M.H. Hazbon, M. Bobadilla del Valle, et al. Global phylogeny of Mycobacterium tuberculosis based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set. J Bacteriol, 188 (2006), pp. 759-772
12. Brudey, J.R. Driscoll, L. Rigouts, W.M. Prodinger, A. Gori, S.A. Al-Hajoj, et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol, 6 (2006), pp. 23

13. Blackwood, C. He, J. Gunton, C.Y. Turenne, J.W. Kabani, A.M. Kabani. Evaluation of recA sequences for identification of Mycobacterium species. J Clin Microbiol, 38 (2000), pp. 2846-2852

14. Durmaz, S. Gunal, Z. Yang, I.H. Ozerol, M.D. Cave. Molecular epidemiology of tuberculosis in Turkey. Clin Microbiol Infect, 9 (2003), pp. 873-877

15. Elia-Pasquet, F. Dabis, J. Texier-Maugien, S. Dessus-Babus, J. Meynard, M. Bouiges, et al. Transmission of tuberculosis in Gironde: epidemiologic investigation by genomic analysis of Mycobacterium tuberculosis. Rev Epidemiol Sante Publique, 48 (2000), pp. 127-136.